PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsSmall cell lung carcinoma
MeSH D055752 - small cell lung carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002283:Bronchogenic carcinoma
0 Companies
0 Drugs
Success rate
D055752: 
Small cell lung carcinoma
17 Companies
3 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaTopotecan Topotecan Teva  2009-09-21   
Novast LaboratoriesTopotecan Topotecan  2016-11-30   
Rising PharmaceuticalsTopotecan Topotecan  2012-08-28   
RocheAtezolizumab Tecentriq  2017-09-20 $4,406.336 M Q4/22-Q3/23 
SandozTopotecan Hycamtin  1996-05-28   
Topotecan Topotecan  2011-02-25   
PfizerTopotecan Topotecan Hospira  2010-06-09   
Dr Reddys LaboratoriesTopotecan Topotecan  2011-03-09   
Sun Pharmaceutical IndustriesTopotecan Topotecan  2013-08-29   
HospiraTopotecan Topotecan  2011-02-02   
Accord HealthcareTopotecan Topotecan  2013-06-26   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
78%
85/109
Phase 2
25%
39/158
Phase 3
18%
9/51
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Roche
Atezolizumab,
Transplatin,
Albumin,
Antithrombin iii,
Tiragolumab,
Ademetionine,
Nepidermin,
Retinol,
Mk3475,
Q2w,
Vp16,
Arm1,
Gemcis,
Ro7616789,
Abt199
Pfizer
Topotecan,
Transplatin,
Antithrombin iii,
Aglatimagene besadenovec,
Figitumumab,
Vicriviroc,
Sodium lactate,
Bevifimod,
Nepidermin,
Microcrystalline cellulose,
Vp16,
Pd0332991,
Tmz
Jazz Pharmaceuticals
Lurbinectedin,
Antithrombin iii,
Vp16
Smithkline Beecham
Topotecan
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use